News | January 09, 2025
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
Increases speed to market for drug developers working on nucleic acid therapeutics
Increases speed to market for drug developers working on nucleic acid therapeutics
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Q2 FY25 Total Income was at Rs. 85.4 crore
Strengthening focus in Alzheimer's disease and neuroscience pipeline
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Subscribe To Our Newsletter & Stay Updated
